MVIRS Stock Overview
A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medivir AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.34 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | -0.22 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -82.23% |
| Change since IPO | -96.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| MVIRS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | -15.4% | 9.0% |
Return vs Industry: Insufficient data to determine how MVIRS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how MVIRS performed against the UK Market.
Price Volatility
| MVIRS volatility | |
|---|---|
| MVIRS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: MVIRS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MVIRS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 10 | Jens Lindberg | www.medivir.com |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma.
Medivir AB (publ) Fundamentals Summary
| MVIRS fundamental statistics | |
|---|---|
| Market cap | SEK 335.00m |
| Earnings (TTM) | -SEK 96.52m |
| Revenue (TTM) | SEK 7.73m |
43.3x
P/S Ratio-3.5x
P/E RatioIs MVIRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVIRS income statement (TTM) | |
|---|---|
| Revenue | SEK 7.73m |
| Cost of Revenue | SEK 76.47m |
| Gross Profit | -SEK 68.73m |
| Other Expenses | SEK 27.79m |
| Earnings | -SEK 96.52m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.86 |
| Gross Margin | -888.81% |
| Net Profit Margin | -1,248.18% |
| Debt/Equity Ratio | 0% |
How did MVIRS perform over the long term?
See historical performance and comparison